Quartz Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.35M Sell
34,994
-388
-1% -$59.5K 2.07% 13
2025
Q4
$4.88M Buy
35,382
+2,970
+9% +$389K 1.82% 19
2025
Q3
$4.16M Buy
32,412
+7,330
+29% +$894K 1.51% 23
2025
Q2
$3.04M Sell
25,082
-137
-0.5% -$15.4K 1.39% 21
2025
Q1
$2.81M Buy
25,219
+7,056
+39% +$751K 1.71% 17
2024
Q4
$1.77M Buy
18,163
+853
+5% +$91K 1.08% 24
2024
Q3
$1.99M Buy
+17,310
New +$1.96M 1.25% 19

Other funds holding NVS

Quartz Partners's NVS Position: Q1 2026 in Review

Quartz Partners reduced its Novartis (NVS) stake by 1.1% in Q1 2026, selling an estimated $59.5K and leaving 34,994 shares worth $5.35M. The position accounts for 2.07% of the portfolio, ranked #13.

Quartz Partners first reported a position in NVS in Q3 2024 and has held it in 7 quarters since. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Quartz Partners held 34,994 shares of Novartis worth $5.35M as of Q1 2026.
  • Quartz Partners sold 388 Novartis shares in Q1 2026, an estimated $59.5K.
  • Novartis made up 2.07% of Quartz Partners's portfolio in Q1 2026, its #13 holding.
  • Quartz Partners first reported a position in Novartis in Q3 2024 and has held it in 7 quarters since.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Quartz Partners's 13F filing for Q1 2026, filed 5 May 2026.